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Abstract
Background
Scabies and head lice are ubiquitous ectoparasitic infestations that are common across the
Pacific Islands. Ivermectin is an effective treatment for both conditions, although the doses
used vary. At a community level, mass drug administration (MDA) with ivermectin is an
effective strategy to decrease prevalence of scabies. To what extent MDA with ivermectin
will also reduce prevalence of head lice is unknown.
Methodology
Head lice prevalence was assessed before and after MDA with oral ivermectin (at a dose of
200 micrograms per kilogram of body weight) administered on day 1 and day 8. The primary
outcome was the change in prevalence of head louse infestation at two weeks compared to
baseline. Longer term efficacy was assessed three months after MDA.
Results
118 participants were enrolled. Baseline prevalence of active head louse infestation was
25.4% (95% CI 18.4–34.0). At three-month follow-up, prevalence was 7.5% (95% CI 2.7–
12.3), a relative reduction of 70.6% (95% CI 72.7%-91.4%, p <0.001). Head louse infestation
was associated with younger age (age10 years: prevalence 46.7%; adjusted odds ratio com-
pared to adults of 7.2, 95%CI 2.0–25.9) and with having at least one other member of the
household with active head louse infestation (adjusted odds ratio 4.3, 95%CI 1.7–11.1).
Conclusions
Head louse infestation is common in the Solomon Islands. This proof of principle study
shows that oral ivermectin at a dose of 200 micrograms per kilogram can reduce the burden
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of active head louse infestation, offering an additional collateral benefit of MDA with ivermec-
tin for scabies control.
Trial registration
ClinicalTrials.gov NCT03236168.
Author summary
Head lice and scabies are both caused by ectoparasites and lead to itchy skin conditions
that are associated with secondary bacterial infections and social stigma. Both are com-
mon in developing countries. In the Solomon Islands, mass treatment of communities
using ivermectin (at dose of 200 micrograms per kilogram) has been shown to be an effec-
tive strategy in reducing scabies prevalence. This study shows that the same dose of iver-
mectin and the same regime of mass drug administration is also effective at reducing the
burden of head louse infestation, offering an additional benefit to community wide
treatment.
Introduction
The human head louse, Pediculus humanus capitis, is an ectoparasitic insect found on the scalp
that is endemic world-wide [1]. Head louse infestation can cause intense scalp itching and
scratching can lead to secondary bacterial infections [2]. In low and middle income countries,
this parasitic skin disease has received little attention in research [3]. Specifically, in the Pacific
region, there is minimal research quantifying its prevalence or potential treatment strategies
[4].
Ivermectin is an oral, semi-synthetic derivative of the avermectin family of lactones that
selectively binds glutamate-gated chloride channels found in invertebrate muscle and nerve
cells thus disrupting neurotransmission in a wide range of human parasites [5]. Oral prepara-
tions of ivermectin can be used to treat head lice [2,6] as well as other blood feeding ectopara-
sitic diseases, including scabies [7,8]. It should be noted that for both, head lice and scabies,
oral ivermectin treatment does not have ovicidal action.
A large trial evaluating the use of ivermectin monotherapy, in difficult-to-treat head louse
infestation, showed that ivermectin at a dose of 400 micrograms per kilogram (kg) on day 1
and day 8, had superior efficacy compared to 0.5% malathion lotion [5]. Small studies have
suggested variable efficacy when a dose of 200 micrograms per kg is used. Single administra-
tion resulted in variable reductions in head lice of 45% - 100% at one week follow up but repeat
administration on day 8 yielded higher reductions (87.5% - 100%) at two-week follow up [9–
13]. These studies have all focused-on treatment of individual patients and not on whole com-
munities where head lice are common and where re-infestation from other community mem-
bers might be anticipated to result in a lower efficacy than that seen in individual treatment
trials.
Scabies, another ectoparasitic disease, has already been shown to be extremely common in
the Pacific [14–16]. Ivermectin, used as part of mass drug administration (MDA), at a dose of
200 micrograms per kg given at a 7-day interval, has been shown to be an effective strategy to
reduce community wide prevalence of scabies in the region [17–20], These programmes might
have ancillary benefits such as treatment of headlice in the communities.
Ivermectin for headlice
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The study we conducted aimed to establish baseline prevalence of head louse infestation in
a rural community in the Solomon Islands and to assess whether MDA using ivermectin, at
the lower dose of 200 micrograms per kilogram (the same regimen already used for scabies
treatment) would be an effective method to lower community prevalence of head lice.
Methods
Ethics statement
The study was approved by the London School of Hygiene and Tropical Medicine (LSHTM)
ethics committee and the National Health Research and Ethics Committee of the Solomon
Islands Ministry of Health and Medical Services. Written consent was obtained from all partic-
ipants by a staff member fluent in both local languages (Pijin and East Kwaio). Parents or
guardians provided written consent for participants aged below 18 years. Children were addi-
tionally asked to provide verbal assent for participation. The study was prospectively registered
on clinicaltrials.gov (NCT03236168).
Study Site
The study was conducted in the campus area of Atoifi Adventist Hospital (AAH) in the East
Kwaio region of Malaita Island, Solomon Islands. The hospital staff and their families live on
campus and create a self-contained community of approximately 200 individuals. The campus
has a school for children aged up to 16 years. Students who attend Atoifi School live on campus
(staff children) or live in villages that surround the campus. All individuals living on AAH
campus and all children and families of children attending Atoifi School were eligible for the
study.
Data collection and ivermectin administration
At baseline participants’ demographic and household data were collected and all individuals
underwent a standardised examination of their skin and scalp.
Scalp examination consisted of direct visual inspection of sites of predilection for head lice:
the back of the ears, temples and neck. This was followed by parting the hair into 4 sections
(first down sagittal plane and then ear to ear). Each section was visually inspected and exam-
ined using a metal nit comb with plastic base and 0.1mm teeth size by the brand InfectoPedicul
manufactured by InfectoPharm. Eggs and lice were as far as possible not deliberately removed
from the hair during the examination to avoid biasing outcome measure assessment by physi-
cal delousing. Scalp examinations were carried out by trained nursing staff at Atoifi Hospital
led by a physician (SC). Prior to study commencement all staff received a standardised half-
day training workshop including practical sessions on clinical examination and use of nit
combs. Ten percent of hair examinations were repeated by an independent examiner to ascer-
tain accuracy of diagnosis.
Adult and nymphal stages of head lice were classified as ‘active head louse infestation’. If
only head lice eggs were seen, this was recorded as ‘egg infestation’. No attempts were made to
differentiate between viable and non-viable eggs.
The diagnosis of scabies was made clinically based on presence of pruritic inflammatory
papules or nodules with a typical anatomical distribution using previously validated criteria
[21]. The distribution and number of scabies lesions were recorded and used to classify sever-
ity of scabies based on classifications used in previous studies in the Pacific region [16,22]. Par-
ticipants were not re-examined for scabies as part of this study.
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Ivermectin was administered as directly observed therapy at a dose of 200 micrograms per
kg of body weight. The first administration of ivermectin was at time of baseline examination.
A second administration of ivermectin was given 7 days later to all study participants (day 8).
Participants with contraindications to ivermectin treatment (weight below 12.5kg, preg-
nancy or breastfeeding) were offered malathion 0.5% lotion for head lice and permethrin 5%
cream for scabies. Participants diagnosed with any non-scabies skin condition were briefly
counselled and, if necessary, advised to attend the medical clinic to obtain treatment as per
standard local protocol.
To assess immediate efficacy, a subgroup of participants was re-examined at 48 hours.
School children were chosen both for convenience sampling and because they were predicted
(from risk factors identified in literature citation) to have highest rates of head louse infesta-
tion. The primary outcome of the study was change in prevalence of head lice at 2 weeks com-
pared to baseline. Longer-term efficacy was assessed by examination at 3 months.
Statistical analysis
For analysis, age was classified into three categories: less than or equal to 10 years, 11–20 years
and over or equal to 21 years of age. Area of residence was classified into two categories: house-
hold in AAH or household out of AAH campus.
We calculated the prevalence of individuals with adult or nymphal stages of head lice on
examination (active head lice) and the prevalence of head lice eggs on examination.
Univariable logistic regression was used to identify risk factors for the presence of head lice
at baseline. Variables associated in the univariable regression analysis were included in a multi-
variable model. We considered age and gender as forced confounders to be included in the
multivariable model.
Treatment efficacy was assessed by comparing the proportion of individuals with head lice,
using a two-sample test of proportion at baseline compared to 48 hours, two weeks and three
months respectively. We calculated the absolute and relative reduction in the prevalence of
both active head louse infestation and egg infestation. Data was analysed with STATA software
version 14.2 (Stata Corporation, College Station, TX, USA).
Results
There were 218 individuals in the study community. Of these, 118 participants consented to
take part in the study (Fig 1). Five participants had contraindications to ivermectin (2 women
were breast feeding and 3 children weighed less than 12.5kg) and were given malathion lotion
and permethrin cream as per protocol.
The median age in the study population was 20 years (interquartile range 10–26). Thirty-
seven individuals (31.4% of cohort) lived in one of the three villages closest to AAH campus
(Table 1). Households outside of the AAH campus were on average larger and had a larger
number of children (3.4) compared to households on the AAH campus (2.4) (p = 0.001).
Baseline prevalence of head lice and scabies
The baseline prevalence of active head louse infestation was 25.4% (95% CI 18.4–34.0). In all
cases where active head louse infestation was identified, head lice eggs were also seen. The
baseline prevalence of head lice eggs (with or without active head louse infestation) was 42.3%
(95% CI 30.8–48.8). Scabies prevalence was 10.2% (95% CI 5.9–16.9) (Table 2). No cases of
crusted scabies were identified. Other skin conditions diagnosed included tinea corporis
(n = 3) and eczema (n = 4).
Ivermectin for headlice
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Fig 1. Study enrolment and follow-up flow diagram [modified from CONSORT guidelines [23]].
https://doi.org/10.1371/journal.pntd.0006825.g001
Table 1. Demographic characteristics of study cohort.
Study cohort (n = 118)
Gender
Male 57 (48.3%)
Female 61 (51.7%)
Age (years)
 10 32 (27.1%)
11–20 31 (26.2%)
 21 55 (46.6%)
Household location
AAH campus 81 (68.6%)
Villages close to AAH 37 (31.4%)
https://doi.org/10.1371/journal.pntd.0006825.t001
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Risk factors for head lice
Active head louse infestation was associated with younger age, with increased risk compared
to adults for both 0–10 years (AOR 7.2, 95% CI 2.0–25.9, p = 0.003) and 11–20 years (AOR 9.1,
95% CI 2.4–34.2, p = 0.001). Infestation was also associated with the presence of other mem-
bers of the household with active lice infestation (AOR 3.9, 95% CI 1.1–14.3, p = 0.040). No
association was seen with gender or location of the house on or off the AAH campus (Table 3).
The presence of head lice eggs was associated with age, with highest risk in children aged
under or equal to 10 years (AOR 5.9, 95% CI 2.0–17.1). Head lice eggs were also associated
with female gender (AOR 3.1, 95% CI 1.3–7.6) (Table 3).
Change in head lice prevalence at 48 hours, 2 weeks and 3 months
Twenty-four out of 28 school-children (85.7%) were re-examined at 48 hours following iver-
mectin administration. The prevalence of active infestation decreased from 45.8% at baseline
to 0%.
At two weeks after MDA, the prevalence of active infestation had declined significantly
(25.6% vs 2.5%, relative reduction (RR) 89.1%, p<0.001) (Table 4).
At three months, the prevalence of active head louse infestation remained significantly
lower than at baseline (25.6% vs 7.5%, RR 70.6%, p<0.001) (Table 4).
The prevalence of head lice eggs was unchanged at two weeks (42.3% vs 41.8%) but reduced
significantly at three months (42.3% vs 19.6%, RR 53.7%, p < 0.001) (Table 4).
Discussion
This is the first study to demonstrate the efficacy of community-based ivermectin administra-
tion for head lice treatment using ivermectin 200 micrograms per kg, administered twice at
day 1 and day 8. This regimen significantly reduced prevalence of active head louse infestation
at both the two-week and three-month follow-up visit.
At 48 hours, none of the subgroup screened had active head louse infestation. This suggests
that the 200 micrograms per kg dose is effective at killing nymphal and adult head lice stages
in this population and that a higher dose (400 microgram per kg) is unlikely to offer any addi-
tional short-term head lice killing benefits.
At two weeks, the prevalence of active head lice in the whole study sample had decreased
significantly (from 25.6% to 2.5%). There was no reduction in head lice eggs at two weeks,
however, this was expected given that head lice eggs are cemented, via glue-like glandular dis-
charge, to the hair shaft and remain attached even after hatching. Therefore, head lice eggs will
still be found even after the active head louse infestation has been treated.
Table 2. Baseline prevalence of head lice and scabies.
Active head louse infestation Head lice eggs Scabies
Categories Cases/total in each category Cases/total in each category Cases/total in each category
Total 30 /118 (25.4%) 50/118 (42.3%) 12/118 (10.2%)
Age (years)
10 14/32 21/32 8/32
11–20 12/31 17/31 1/31
21 4/55 12/55 3/55
Gender
Male 12/61 17/61 4/61
Female 18/57 33/57 8/57
https://doi.org/10.1371/journal.pntd.0006825.t002
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At three months, the effect of the intervention was sustained. The prevalence of active infes-
tation remained significantly lower than baseline. Furthermore, the reduction in active head
louse infestation translated into a reduction in egg prevalence at three months.
Our study also demonstrates that head lice are an extremely common ectoparasitic infec-
tion in the Solomon Islands with prevalence comparable or higher than those reported in
other lower income settings such as Nepal, Brazil and Egypt [3]. This is a significant burden of
disease and further qualitative research is important to elucidate the local attitudes and percep-
tion towards head louse infestation.
The findings of this study highlight an opportunity to concomitantly target two common
ectoparasitic infections at community level with a single intervention strategy. Showing evi-
dence for additional benefits of MDA may increase engagement of local communities and sup-
port from local authorities towards community-wide programs and enables control of head
louse infestation to be integrated with growing control programs for neglected tropical dis-
eases such as scabies.
Our study had some limitations. First, MDA coverage was 54% of the eligible population.
We did not record the age of non-participants and, as the prevalence of headlice is higher in
children, this may have biased our overall prevalence estimate. Despite this our intervention
demonstrated efficacy of MDA. Second, prevalence of active head louse infestation did
increase slightly at three months compared to two weeks. This may well reflect re-introduction
of head lice from untreated members of the community or surrounding villages. Expanding
the population that receives treatment may reduce the risk of re-introduction and thus
Table 3. Multivariate analysis of risk factors for head lice.
Active head louse infestation Head lice eggs
Adjusted Odds ratio (95% CI) p-value Adjusted Odds ratio (95% CI) p-value
Age (y)
10 7.2 (2.0–25.9) 0.003 5.9 (2.0–17.1) 0.001
11–20 9.1 (2.4–34.2) 0.001 5.2 (1.8–15.0) 0.002
 21 1.0 - 1.0 -
Gender
Male 1.0 - 1.0 -
Female 1.5 (0.6–4.1) 0.377 3.1 (1.3–7.6) 0.010
Location of house
AAH campus 1.0 - 1.0 -
Villages 1.0 (0.3–3.2) 0.956 1.5 (0.5–4.9) 0.491
Others infested in household
None 1.0 1.0
At least one person with active head louse infestation 3.9 (1.1–14.3) 0.040 2.2 (0.7–6.7) 0.179
https://doi.org/10.1371/journal.pntd.0006825.t003
Table 4. Change in prevalence of head louse infestation over 3 months.
Head louse
infestation
Baseline
prevalence
2-week
prevalence
3-month
prevalence
Absolute Reduction in Prevalence (baseline to
3 months)
Relative reduction in prevalence
(baseline to 3 months)
Cases/n (%) Cases/n
(%)
Cases/n (%) Percentage points (95% CI) Percentage points (95%
CI)
P value
Active 30/118 (25.6) 3/117
(2.5)
8/107
(7.5)
18.12 (8.6–27.2) 70.6
(72.7–91.4)
<0.001
Eggs 50/118 (42.3) 49/117 (41.8) 21/107 (19.6) 22.7 (11.1–34.4) 53.7
(28.3–70.1)
<0.001
https://doi.org/10.1371/journal.pntd.0006825.t004
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improve long-term reduction in head lice prevalence at community level. Finally, we did not
differentiate between viable eggs and non-viable eggs. Being able to reliably distinguish viabil-
ity of eggs would have yielded a more accurate estimate of active head louse infestation in the
community and could be considered in future studies.
Our study demonstrated the effectiveness of a two-stage administration of ivermectin at a
dose of 200microgram per kg for the treatment of head lice. A reduction in head lice preva-
lence is likely to be an ancillary benefit of the scale-up of scabies control programmes in the
Pacific region and elsewhere. As with other ectoparasitic infestations, head lice are a common
and under-recognised parasitic infestation in the Solomon Islands. Fully measuring the impact
of MDA programs can maximise the potential benefits to the community and aid community
engagement with the intervention. Further delineating the full range of benefits of ivermectin
MDA should be a priority for scabies control programmes.
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